)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Shenzhen New Industries Biomedical Engineering
Shenzhen New Industries Biomedical Engineering (300832) investor relations material
Shenzhen New Industries Biomedical Engineering Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary27 Oct, 2026
Executive summary
9M 2026 revenue rose 7.97% YoY to ¥3.701bn; net income attributable to shareholders increased 15.42% to ¥1.391bn.
Adjusted for non-recurring items, 9M net profit increased 16.62% YoY to ¥1.324bn.
Financial highlights
Q3 revenue was ¥1.280bn, up 3.03% YoY; net profit was ¥522.9m, up 20.55%, and adjusted net profit was ¥499.9m, up 21.98%.
9M profit before tax reached ¥1.587bn, up 16.14% YoY; profit excluding FX effects grew 23.42%.
9M non-recurring gains totaled ¥66.2m, including ¥61.6m in investment income.
Outlook and guidance
230 company-produced and partner automation lines were installed or sold in 9M, supporting progress toward the full-year line installation/sales target.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Shenzhen New Industries Biomedical Engineering
- Revenue and profit rose double digits, with strong reagent growth and overseas momentum.300832
Q2 2026 - 2025 revenue rose 0.91% to ¥4.58B, with net profit down 11.39% amid strong overseas growth.300832Q4 2025
- Q1 saw modest revenue and profit growth, strong cash flow, and robust overseas reagent sales.300832Q1 2026
- Revenue up 3.28% in Q3 2025, but net profit down 9.72% as domestic sales declined.300832Q3 2025
- Revenue up 10.12% and net profit up 2.65%, but cash flow dropped sharply on ERP transition.300832Q1 2025
- H1 2025 revenue fell 1.18% to ¥2.18B, net profit down 14.62%, overseas sales up 19.57%.300832Q2 2025
- Q3 revenue and profit rose double digits year-over-year, driven by strong product and market growth.300832Q3 2024
- Net profit surged 20.42% year-over-year on robust sales and margin gains.300832Q2 2024
Next Shenzhen New Industries Biomedical Engineering earnings date
Q4 202616 Apr, 2027
Shenzhen New Industries Biomedical Engineering
Next Shenzhen New Industries Biomedical Engineering earnings date
Q4 202616 Apr, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Shenzhen New Industries Biomedical Engineering Co., Ltd., often referred to as Snibe, is a prominent bio-medical company based in Shenzhen, China. Founded in 1995, the company specializes in the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents. Snibe offers a range of products, including immunoassay systems, clinical chemistry equipment, molecular diagnostics, point-of-care testing solutions, lab automation, and integrated systems. These products are utilized by hospitals and laboratories both within China and internationally. The company is headquartered in Shenzhen, Guangdong, and its shares are listed on the Shenzhen Stock Exchange.